Open AccessIncreased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications
Author(s) -
S. T. Knudsen,
C. R. Foss,
P. L. Poulsen,
N.H. Andersen,
Mogensen Ce,
Lars Melholt Rasmussen
Publication year - 2003
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.0.1490039
Subject(s) - medicine , osteoprotegerin , endocrinology , microalbuminuria , diabetes mellitus , type 2 diabetes , glycemic , diabetic retinopathy , albuminuria , receptor , activator (genetics)
Osteoprotegerin (OPG) is a newly identified inhibitor of bone resorption. Recent studies indicate that OPG also acts as an important regulatory molecule in the vasculature. Plasma levels of OPG seem to be elevated in subjects with diabetes as well as in non-diabetic subjects with cardiovascular disease. The aim of the present study was to examine the association between plasma OPG levels and microvascular complications and glycemic control in patients with type 2 diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom